
The prospective cohort clinical trial evaluated the safety and efficacy of TRUS-guided intraprostatic betamethasone injections in 45 patients with refractory chronic nonbacterial prostatitis (CNP). Six injections were administered, and outcomes were assessed using NIH-CPSI, IPSS, IIEF, GRA, and VAS at 1, 4, and 12 weeks post-injection. Pain and urinary symptoms significantly improved, with 71% of patients achieving success (≥25% symptom reduction) on the NIH-CPSI at 1 week, dropping to 55.6% and 44.4% at 4 and 12 weeks, respectively. The GRA scores indicated successful pain control in 82%, 71%, and 64.4% at the same intervals. Improvements in IPSS and IIEF scores were observed but modest. These findings suggest that intraprostatic betamethasone injections are a simple, safe, and effective option for managing refractory CNP with predominant pain and urinary symptoms.
Like
Save
Share